<DOC>
	<DOCNO>NCT02348658</DOCNO>
	<brief_summary>This phase 1 , randomize , open-label , crossover study evaluate food-effect single oral dose TAK-536TCH final formulation tablet healthy adult male participant .</brief_summary>
	<brief_title>A Phase 1 Food Effect Study TAK-536TCH Final Formulation Tablet</brief_title>
	<detailed_description>The purpose study evaluate food effect pharmacokinetics safety single oral dose TAK-536TCH fast fed condition morning healthy adult male participant .</detailed_description>
	<criteria>1 . In opinion investigator subinvestigator , participant capable understand comply protocol requirement . 2 . The participant sign date write , informed consent form prior initiation study procedure . 3 . The participant healthy Japanese adult male . 4 . The participant age 20 35 year , inclusive time inform consent . 5 . The participant weighs least 50.0 kg body mass index ( BMI ) 18.5 25.0 kilogram per square meter ( kg/m^2 ) , inclusive Screening . 1 . Participant systolic blood pressure lessthan ( &lt; ) 90 millimeter mercury ( mmHg ) Screening . 2 . Participant suspect hypotension associate physical finding , dizziness postural , facial pallor , cold sweat base evaluation/physical examination Screening , Day 1 Period 1 , administration Period 1 . 3 . The participant receive study drug within 16 week ( [ i.e . ] , 112 day ) prior study drug administration Period 1 . 4 . The participant receive TAK491* , TAK536 , amlodipine , hydrochlorothiazide previous clinical study therapeutic agent . 5 . The participant uncontrolled , clinically significant neurologic , cardiovascular , pulmonary , hepatic , renal , metabolic , gastrointestinal , urological , endocrine disease , abnormality ( disease study ) , could impact ability participant participate potentially confound study result . 6 . Participant know hypersensitivity drug . 7 . Participant positive urine drug result drug abuse Screening . 8 . Participant history drug abuse ( define illicit drug use ) history alcohol abuse within 2 year prior Screening visit unwilling agree abstain alcohol drug throughout study . 9 . Participant require prohibit concomitant drug , vitamin , food product list prohibited concomitant drug food table . 10 . Participant current recent ( within 6 month ) gastrointestinal disease would expect influence absorption drug ( i.e. , history malabsorption , esophageal reflux , peptic ulcer disease , erosive esophagitis , frequent [ per week ] occurrence heartburn , surgical intervention [ e.g. , cholecystectomy ] ) . 11 . Participant history cancer . 12 . Participant positive test result hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody , human immunodeficiency virus ( HIV ) antibody/antigen , serological reaction syphilis Screening . 13 . Participant poor peripheral venous access . 14 . Participant undergone whole blood collection least 200 mL within 4 week ( 28 day ) least 400 mL within 12 week ( 84 day ) prior study drug administration Period 1 . 15 . Participant undergone whole blood collection least 800 mL total within 52 week ( 364 day ) prior study drug administration Period 1 . 16 . Participant undergone blood component collection within 2 week ( 14 day ) prior study drug administration Period 1 . 17 . Participant hemoglobin value le 12.5 g/dL laboratory test Screening prior study drug administration Period 1 . 18 . Participant clinically significant ECG abnormality Screening prior study drug administration Period 1 . 19 . Participant abnormal laboratory value Screening prior study drug administration Period 1 suggest clinically significant underlying disease participant follow lab abnormality : alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 1.5fold upper limit normal range . 20 . Participant , opinion investigator , unlikely comply protocol unsuitable reason .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Pharmacological therapy</keyword>
</DOC>